1. SCOTT W. BAUMGARTNER, M.D.
Spokane, WA 99292 ∙ 858-736-1321 ∙ drswb49@hotmail.com
CLINICAL RESEARCH, EDUCATION, & MEDICAL AFFAIRS
PROFESSIONAL EXPERIENCE
drB CONSULTING, LLC CURRENT
OWNER & PRINCIPAL CONSULTANT
Providing consultation on numerous Healthcare issues. Clients include:
• Grunenthal GMBH, Aachen, Germany
• Ardea Biosciences, San Diego, CA
ARDEA BIOSCIENCES (A MEMBER OF THE ASTRA ZENECA GROUP) 2011 – JULY 2016
VICE PRESIDENT, MEDICAL AFFAIRS, (SEPTEMBER 2014 TO JULY 2016)
• Physician lead for Ardea /AstraZeneca Medical Affairs activities for gout franchise
• Physician Member on Global Brand and Payer Teams in support of a global launch
• Physician lead for publication planning
• Responsibilities/accountabilities for Medical Education, internal training, marketing company medical communications,
opinion leader interactions, professional society/organization support and interactions, strategy and planning
VICE PRESIDENT, CLINICAL RESEARCH & DEVELOPMENT (2013 TO 2014)
• Head of Clinical Development
o Member of Ardea Executive Management Team
o Accountability for management, budget development and approval, resourcing of Clinical Operations,
Biostatistics, Data Management functions (45 employees)
o Responsibility for clinical trial design and execution
o Involved in Business Development activities
• Global Brand Physician AstraZeneca
o Physician Member on Global Brand Team and Global Payer Team
o Physician Lead to AstraZeneca Global Medical Affairs
o Physician Lead for AstraZeneca Publication Planning
EXECUTIVE MEDICAL DIRECTOR, ARDEA BIOSCIENCES (2011 TO 2013)
• Medical Scientist on phase 3 clinical program
• Co-lead, Study Management Teams
• Medical input, review, and section authorship of clinical trial protocols, investigator brochure, regulatory documents
• Medical input to program strategy
• Co-developed Medical Affairs strategy, medical lead for publication planning, medical lead for advisory board
development and execution
AMGEN, INC. 2005-2011
MEDICAL DIRECTOR, GLOBAL CLINICAL DEVELOPMENT, INFLAMMATION, (GLOBAL DEVELOPMENT LEAD ENBREL RHEUMATOLOGY 2007-
2010, PHASE 2 DEVELOPMENT OF BRODALUMAB, 2009-2011)
 Point of accountability for evidence generation and scientific communication
 Develop and execute the global scientific/medical evidence plan
 Provide medical and scientific input into key deliverables (e.g., regulatory filings and interactions, clinical study reports,
publications)
 Oversee activities related to planning for studies
o Phase 2 program in 4 indications for brodalumab, an IL-17 inhibitor
o Phase 3 and 4 trials for Enbrel
 Interpret and integrate the results of research programs (e.g. study data, competitor data, publications) into the overall
program strategy
 Review and approve publication plan and publications
 Perform due diligence for licensing proposals and support partner relationships

2.  Present and defend budgets and resource requirements to Therapeutic Area Steering Committee
 Present to review boards and upper management
 Medical lead for interactions with regulatory agencies including End of Phase 2 meetings
 Joint accountability with regulatory for Pediatric Investigational Plan for 4 indications
ASSOCIATE DIRECTOR, MEDICAL AFFAIRS, INFLAMMATION (2005-2007)
• Led the Medical Affairs Team for Enbrel Rheumatology
• Led development and execution of evidence generation activities
o Provided medical input into study-related documents (e.g. study concept documents and protocols, clinical study
reports)
o Medical monitor on clinical trials
o Lead or provided input to regional advisory boards
o Reviewed Investigator Sponsored Study (ISS) proposals and represented them at appropriate review boards
o Authored, reviewed and approved publication plan and publications
• Accountable for planning and developing relationships with academic and medical societies, Opinion Leaders, and
relevant professional organizations
• Provided medical input to the commercial Brand Planning process
• Medical Director responsible for input to Corporate Accounts and Access strategy and tactics
THE PHYSICIANS CLINIC OF SPOKANE 1995 – 2005
PRESIDENT OF THE BOARD, MEDICAL DIRECTOR
• President of Board of Directors of a Multi-specialty clinic
• With administrator prepared budgets and financial reports
• Lead strategic planning
• Lead mergers with 3 practices
• Responsible for recruiting new physicians
• Managed care and 3rd party payer negotiations
• Represented the clinic to external customers and public
MEDICAL DIRECTOR, CLINICAL RESEARCH CENTER
• Established research center which eventually employed 4 full time clinical coordinators and an administrative assistant.
• Prepared budget, tracked financials, represented clinic to sponsors
• Served as principal investigator or sub-investigator on over 100 clinical trials including phase 1 through 4
PRIVATE PRACTICE RHEUMATOLOGY
THE PHYSICIANS CLINIC OF SPOKANE, SPOKANE, WA, 1985 - 2005
ARTHRITIS ASSOCIATES OF COLORADO SPRINGS, COLORADO SPRINGS, CO, 1980 – 1985
MEDICAL LICENSURE
State of Washington
EDUCATION
Fellowship: Rheumatology University of Colorado Denver, CO1978 - 1980
Internal Medicine University of Colorado Denver, CO, 1976 - 1978
Residency: Internal Medicine Internship, University of Colorado Denver, CO, 1975 - 1976
Medical School: University of Washington School of Medicine, Seattle, WA1971 - 1975
Undergraduate: B.S. Biology - Magna cum Laude, Seattle University, Seattle, Washington1967 - 1971
ACADEMIC APPOINTMENTS
Faculty, Family Medicine Spokane, Residency Program, 1986 – 2005
Faculty, Internal Medicine Spokane Residency Program, 1986 – 2005
Clinical Assistant Professor of Medicine, Rheumatology, University of Washington, 1986 - 2005
Clinical Assistant Professor of Medicine, Rheumatology, University of Colorado, 1983 - 1985
BOARD CERTIFICATIONS
Association of Clinical Research Professionals, Nov. 8, 2002
American Board of Internal Medicine, Subspecialty Rheumatology, June 17, 1980
American Board of Internal Medicine, Sept 13, 1978

3. National Board of Medical Examiners, 1976
Certified Clinical Research Investigator
MEMBERSHIPS & ACTIVITIES
Washington State Medical Association, 1985-2005
Spokane County Medical Society, 1985-2005
Spokane Society of Internal Medicine, 1986-2005
American College of Physicians/ASIM, Member, 1980-2005
American College of Rheumatology, Fellow, 1980
Alpha Omega Alpha, 1975
PUBLICATIONS, MANUSCRIPTS
Lewis, TL, Lain D, Baumgartner, SW, “Comparison of Diflunisal and Piroxicam in the Management of Patients with Osteoarthritis’,
Clinical Therapies, Vol. 9, Suppl. C., 1986
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K,
Widmer MB, Blosch CM: Treatment of Rheumatoid Arthritis With a Recombinant Human Tumor Necrosis Factor Receptor (p75)-fc
Fusion Protein. New England Journal of Medicine 337:146, 1997
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ,
Ruderman EM, Blosch CM, Lange MLM, McDonnell ND, Weinblatt ME: Etancercept Therapy in Rheumatoid Arthritis, A
Randomized, Controlled Trial, Ann Internal Med. 1999; 130:478-486
Baumgartner SW, Tumor Necrosis Factor Inactivation in the Management of Rheumatoid Arthritis, Southern Medical Journal
2000;93(8): 753-759
Larry W. Moreland, Stanley B. Cohen, Scott W. Baumgartner, Elizabeth A. Tindall, Ken Bulpitt, Richard Martin, Michael Weinblatt,
James Taborn, Arthur Weaver, Daniel J Burge, Michael H. Schiff, Long-term Safety and Efficacy of Etanercept in Patients with
Rheumatoid Arthritis, The Journal of Rheumatology 2001; 28:6
Roy M. Fleischmann, Scott W. Baumgartner, Elizabeth A. Tindall, Arthur L. Weaver, Larry W. Moreland, Michael H. Schiff, Richared
W. Martin, and George T. Spencer-Green, Response to Etanercept (Enbrel®) in Elderly Patients with Rheumatoid Arthritis: A
Retrospective Analysis of Clinical Trial Results, The Journal of Rheumatology 2003; 30:4
Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB: Etanercept (Enbrel) in Patients with
Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in disability, Journal of Rheumatology, Vol 31,
No. 8, 1532-1537, 2004
Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB: Pneumococcal Vaccine Response in
Psoriatic Arthritis Patients During Treatment with Etanercept, Journal of Rheumatology, Vol. 31, No. 7, 1356-1361, 2004
Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P, Long- term safety of etanercept in elderly patients with
rheumatic diseases, Annals of Rheumatic Diseases 2006;65: 379-384.
Inman R, Clegg D, Davis JC, Whitmore JB, Solinger A, Baumgartner S, Etanercept in adult patients with early onset ankylosing
spondylitis, J Rheum 2006;33(8):1634-1636.
Weisman M, Paulus H, Burch F, Kivitz A, Fierer J, Dunn M, Kerr D, Tsuji W, Baumgartner S, A placebo-controlled, randomized,
double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid
diseases Rheumatology 2007 Jul;46(7):1122-5.
Bingham CO, Ince A, Haraoui B, Keystone EC, Chon Y, Baumgartner S, Effectiveness and safety of etanercept in subjects with RA
who have failed infliximab therapy: 16-week, open-label observational study, Current Medical Research and Opinion, 25(5), 2009,
1131-1142

4. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S,
Furst DE, Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis, Ann Rheum
Dis 2010; 69: 1612-1617
Lovell D, Wallace C, Ilowite N, Reiff A, Chon Y, Baumgartner S, Giannini E, Safety of up to 8 years of continuous etanercept therapy
in patients with juvenile rheumatoid arthritis, Arthritis Rheum 2008; 58(5): 1496-1504
E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff,
G. Higgins, B. Gottlieb, N. G. Singer, for the Pediatric Rheumatology Collaborative Study
Group, Y. Chon, S.-L. Lin, and S. W. Baumgartner, Long-Term Safety and Effectiveness of Etanercept in Children with Selected
Categories of Juvenile Idiopathic Arthritis, Arthritis Rheum 2009; 60 (9); 2794-2804
Joachim Sieper, Andy Koenig, Scott Baumgartner, Carole Wishneski, Joanne Foehl, Bonnie Vlahos, Bruce Freundlich, Analysis of
uveitis rates across all etanercept ankylosing spondylitis clinical trials, Ann Rheum Dis 2010;69:226–229
Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner S, Predictors of radiographic progression in
rheumatoid arthritis patients treated with methotrexate, J Rheum 2011; 38:2;242-246
ME Weinblatt, JM Bathon, JM Kremer, RM Fleischmann, MH Schiff, RW Martin, SW Baumgartner, GS Park, EL Mancini, MC
Genovese, Safety and efficacy of Etanercept Beyond 10 Years of Therapy in North American Patients with Early and Long-Standing
Rheumatoid Arthritis, Arthritis Care & Research 63(3) 2011, 373-382
Edward H. Giannini DrPH, MSc1,*,†, Norman T. Ilowite MD2, Daniel J. Lovell MD, MPH1, Carol A. Wallace MD3, C. Egla Rabinovich
MD4, Andreas Reiff MD5, Gloria Higgins PhD, MD6, Beth Gottlieb MD, MS7, Yun Chon PhD8, Nan Zhang PhD8, Scott W.
Baumgartner MD8 Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic
arthritis, Arthritis & Rheumatism 2010, 62:11, 3229-3264
Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCroskery P, Baumgartner S, Markenson JA, Rheumatoid Arthritis
Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Studies; Safety and Etanercept Utilization Analyses from the
RADIUS 1 and RADIUS 2 Registries, J Rheum 2011; 38:1; 1-8
Alice B. Gottlieb MD PhD, Kenneth Gordon MD, Edward H. Giannini MSc DrPH, Philip Mease MD, Juan Li PhD, Yun Chon PhD, Judy
Maddox DO, Haoling H. Weng MD MHS, Joseph Wajdula PhD, Shao-Lee Lin MD PhD, Scott W. Baumgartner MD, Clinical Trial
Safety and Mortality Analysis in Patients Receiving Etanercept Across Approved Indications, Journal of Drugs in Dermatology 2011;
10 (3): 289-300
Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW, Persistence with Anti-Tumor Necrosis
Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry, J Rheum 2011; 38:7;
doi.10.3800/jrheum.101142 (Early Release May 15, 2011)
David M. Pariser, MD; Craig L. Leonardi, MD; Kenneth Gordon, MD; Alice B. Gottlieb, MD, PhD; Stephen Tyring, MD, PhD; Kim A.
Papp, MD; Joanne Li, PhD; Scott W. Baumgartner, MD, Integrated Safety Analysis: Short- and Long-Term Safety Profiles of
Etanercept in Patients with Psoriasis, In Press, Journal of the American Academy of Dermatology, doi: 10.1016/j.jaad.2011.07.040
Jie Zhang PhD, Ying Shan MD MPH, George Reed PhD, Joel Kremer MD, Jeffrey Greenberg MD, Scott Baumgartner, MD, Jeffrey R
Curtis MD MS MPH, Thresholds in Disease Activity for Switching Biologics in RA Patients, Arthritis Care & Research, 63(12), 1672-
1679, 2011
Varni JW, Globe DR, Gandra SR, Harrison DJ, Hooper M, Baumgartner S, Health-related quality of life of pediatric patients with
moderate to severe plaque psoriasis: comparisons to four common chronic diseases, European Journal of Pediatrics 171:485-492,
2012
Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA, A Dose-Response Meta-Analysis for Quantifying Relative Efficacy of
Biologics in Rheumatoid Arthritis, Clinical Pharmacology & Therapeutics, 90;6: 828-835, 2011
Papp KA, Leonardi C, Menter A, Ortonne J, Krueger JG, Krikorian G, Aras G, Li J, Russell CB, Thompson EHZ, Baumgartner S,
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis, New England Journal of Medicine, 355;13: 1181-1189, 1012

5. Fleischmann R, Kerr B, Yeh L, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner J, Baumgartner S,
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of Lesinurad and febuxostat in gout
patients with hyperuricaemia, Rheumatology Advance Access published February 8, 2014, doi:10.1093/rheumatology/ket487
Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R, A world of hurt: failure to achieve treatment goals in patients with
gout requires a paradigm shift, Postgraduate Medicine 2015; Early Online 1-7, DOI:10.1080/00325481.2016. 1113840
An open-label, 6-month study of allopurinol safety in gout: The LASSO study, Becker M, Fitzpatrick D, Choi H, Dalbeth N, Storgard
C, Cravets M, Baumgartner, S, Seminars in Arthritis and Rheumatism 2015; open access dx.coi.org/10.1016/jsemarthrit.
2015.05.005
Doghramji P, Fermer S, Wood R, Morlock R, Baumgartner S. Management of gout in the real world: current practice versus
guideline recommendations. Postgrad Med. 2016 Jan; 128(1):106-14. doi: 10.1080/00325481.2016.1114878. Epub 2015 Nov 23
PUBLICATIONS, ABSTRACTS
Baumgartner SW, Moreland LW, Schiff MH, Tindall E, Fleischmann R, Weaver AL,Ettlinger R, Gruber BL, Katz RS, Skosey JL, Lies RB,
Robinson A, Blosch CM: “Double-blind, Placebo-controlled Trial of Tumor Necrosis Factor Receptor (p80) Fusion Protein (TNFR:fc)
in Active Rheumatoid Arthritis”. Arthritis and Rheumatism, 39; 9 (suppl): S74, 1996.
Baumgartner SW, Moreland LW, et al.: Phase III and long-term treatment of DMARD failing rheumatoid arthritis patients with TNF
receptor p75 fc fusion protein. Presented at EULAR ’97, Vienna Austria 1997.
Moreland LW, Baumgartner SW, Schiff MH et al.: Optimal dose of TNF receptor P75 fusion prtoein. Arthritis and Rheumatism, Vol.
41, N0. 9, 1998
Baumgartner SW, Moreland LW, Schiff MH, et al.: Response of elderly patients to TNF receptor P75 fusion protein. Arthritis and
Rheumatism, Vol. 41, 1998
Baumgartner SW, Morelend LW, Schiff MH, Tindall E, Fleischmann RM, Weaver A, Ettlinger RE, Gruber BL, Katz RS, Skosey JL, Lies
RB, Robinson A, Blosch C: Double-blind, placebo controlled trial of tumor necrosis factor receptor fusion protein (TNFR:fc) in active
rheumatoid arthritis (abstract), J Invest Med 44:23A, 1996
Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Spencer-Green GT: Improvement in Disability in RA
Patients with Early vs Established Disease treated with Enbrel, (abstract), Arthritis and Rheumatisms, Vol 43, No. 9 (suppl), S230,
2000.
Moreland LM, Cohen SB, Baumgartner SW, Schiff MH, Tindall EA, Bukpitt K, Burge DJ: Long-Term Use of Enbrel in Patients with
DMARD-Refractory Rheumatoid Arthritis (abstract), Arthritis and Rheumatism, Vol 43, No. 9 (suppl), S270, 2000
Klareskog L, Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Kalden JR, Whitmore JB, Tsuji WH, The safety and efficacy of
over seven years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe
2005;64(suppl III):410. Abstract #SAT0006.
Klareskog L, Moreland LW, Cohen SB, Kalden , JR, Wajdula J, Chon Y, Baumgartner SW, Tsuji WH (Abstract) Safety and efficacy of
over eight years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe, EULAR 2006
Kremer JM, Reed G, White B, Baumgartner, Lin S-L, An analysis of risk factors and effect of treatment on the development of
cardiovascular disease in patients with rheumatoid arthritis, EULAR 2006
Greenberg, Lin S, Dektor D, Baumgartner S, Chi E, White B, Dabbous O, Montgomery M, Hinkle K, Reed G, Abramson S, Kremer J
(Abstract) Association of duration of TNF antagonist treatment with reduction in cardiovascular outcomes in RA patients, ACR
2006

6. Weinblatt M, Keystone E, Cohen M, Baumgartner S, Freundlich B, Li J, Chon Y, Predictors of poor radiographic response in
rheumatoid arthritis subjects treated with methotrexate: Preliminary analysis from the ERA and TEMPO studies (Abstract)
2006;54:S181-S182.327
Gu N, Huang X, Patel V, Baumgartner S, Fox K, and Chiou CF (Abstract) Assessing dosing patterns of TNF antagonists and associated
costs for rheumatoid arthritis patients treated in routine clinical practice, Association of Managed Care Pharmacists 2007
Klareskog L, Moreland LW, Cohen SB, Kalden JR, Wajdula J, Chon Y, Lin S-L, Baumgartner SW (Abstract) Safety and efficacy of over
9 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe, Annals of
Rheujmatic Disease, 2007;66:177. THU0170
Engel-Nitz NM, Huang X, Globe D, Baumgartner S, Dosing patterns and costs of adalimumab, etanercept, and infliximab among
patients with rheumatoid arthritis, EULAR 2007
Lovell D, Giannin E, Wallace C, Ilowite N, Reiff A, Chon Y, Lin S-L, Baumgartner S, Safety of over 8 years of continuous etanercept
therapy in patients with juvenile rheumatoid arthritis, Annals of Rheumatic Disease 2007;66:112. OP0191
Kim Papp Craig Leonardi, Alan Menter, Jean-Paul Ortonne, Gregory Kricorian, Juan Li, Elizabeth Thompson, Scott Baumgartner,
Efficacy and Safety of AMG 827 in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase 2, Randomized, Double-
blind, Placebo-controlled Study, Abstract number FC22-02, accepted as oral presentation World Congress of Dermatology, May
2011
Kim Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, Scott Baumgartner, Elizabeth HZ Thompson, Brian Ortmeier, Girish
Aras, Gregory Kricorian, Health-Related Quality of Life in Subjects Undergoing Therapy With AMG 827 For Moderate to Severe
Plaque Psoriasis, European Academy of Dermatology and Venereology, Lisbon, Portugal; October 20-24, 2011 Poster PO1094
Baumgartner S, Choi H, Dalbeth N, Fitzpatrick D, Cravets M, Storgard C, Allopurinol Dose Titratioin and Efficacy: A Large-Scale,
International, 6 Month, Multicenter, Prospective Study, Arthritis Rheum 2013: 65 (Suppl): S503
Singh J, Storgard C, Baumgartner S, Morlock R, High-dose allopurinol in France, Germany, Italy, Spain, and the United Kingdom,
Ann Rheum Dis 2013;72(Suppl3):713
Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R, Assessing Serum Uric Acid (sUA) Levels, Flare Rates, and Tophi in
Patients with Gout Treated with Xanthine Oxidase (XO) Inhibitors in the United Sates, Ann Rheum Dis 2013;72(Suppl3):770
Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R, Patients Who Flare Despite Reaching EULAR/ACR-recommended
Serum Urate Target, Ann Rheum Dis 2013;72(Suppl3):713
Becker M, Fitzpatrick D, Storgard C, Cravets M, Baumgartner S, A Large-Scale, Multicenter, Prospective, Open Label, 6-Month Study
to Evaluate the Safety of allopurinol Monotherapy in Patients with Gout, Arthritis Rheum 2013;65(Suppl): S502
Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R, More Than One-Third of Patients Reach Serum Urate Target and
Continue to Report Multiple Flares, Arthritis Rheum 2013;65(Suppl):S501
Morlock R, Baumgartner S, Storgard C, Use of High-Dose Allopurinol to Reach Serum Uric Acid Targets in Patients With Gout Across
Multiple Countries, Arthritis Rheum 2013;65(Suppl):S502
Wood R, Johnson J, Morlock R, Baumgartner S, Ramachandran S, Gout Patients Treated with Conventional Urate Lowering
Therapy: Association Between Disease Control and Work Productivity, EULAR 2014, Abstract H3532
Wood R, Johnson J, Morlock R, Baumgartner S, Ramachandran S, Gout Patients Treated with Conventional Urate Lowering
Therapy: Association Between Disease Control and Health-Related Quality of Life, EULAR 2014, Abstract H3531
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Adler S, Bhakta N, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F,
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function, American
College of Rheumatology, San Francisco 2015

7. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Adler S, Bhakta N, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F, Efficacy
and Safety in Patients With Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an
Extension Study, American College of Rheumatology San Francisco 2015
Terkeltaub R, Perez-Ruiz F, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Dalbeth N, The Safety and Efficacy of
Lower Serum Urate Levels: a Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors, American
College of Rheumatology, San Francisco 2015
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F, Lesinurad, a
Novel Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat, in Patients With Tophaceous Gout, American
College of Rheumatology, San Francisco 2015
Saag K, Bardin T, So A, Khanna P, Storgard C, Baumgartner S, Fung M, Bhakta N, Adler S, Kopicko J, Becker M, Analysis of Gout
Subjects Receiving Lesinurad and Allopurinol Combination Therapy by Baseline Renal Function , American College of Rheumatology
San Francisco 2015
Perreault S, Nuevo J, Baumgartner S, Morlock R, Gout Control Among Hypertensive Patients With Gout and the Relationship to
Onset of End-stage Renal Disease, International Congress of Pharmicoepidemiology and Therapeutic Risk management (ICPE),
Boston 2015
Perreault S, Nuevo J, Baumgartner S, Morlock R, Adherence and Persistence to Allopurinol Among Hypertensive Patients with
Gout, ICPE, Boston 2015